



Contents lists available at SciVerse ScienceDirect

Tetrahedron: Asymmetry

journal homepage: www.elsevier.com/locate/tetasy

Asymmetric synthesis of (*R*)-[2,2-²H₂]-1-aminocyclopropane-1-phosphonic acid (ACPP derivative) conformationally constrained ACC analogue using a chiral sulfinyl auxiliary

Wanda H. Midura*, Aneta Rzewnicka

Centre of Molecular and Macromolecular Studies, Polish Academy of Sciences, Department of Heteroorganic Chemistry, 90-363 Lodz, Sienkiewicza 112, Poland

ARTICLE INFO

Article history:

Received 22 May 2013

Accepted 29 May 2013

Available online xxxx

ABSTRACT

The asymmetric cyclopropanation of vinylphosphonate using (*S*)-dimethylsulfonium-(*p*-tolylsulfinyl)methylide was applied to obtain a dideuterated cyclopropyl sulfoxide. A three-step synthesis of enantiopure (+)-(1*R*)-1-amino-2,2-dideuteriocyclopropanephosphonic acid (+)-**17-d₂** was developed.

© 2013 Elsevier Ltd. All rights reserved.

1. Introduction

1-Aminophosphonic acids, defined as analogues of amino acids in which the carboxylic group is replaced by a phosphonic acid moiety, are the subject of increasing interest¹ due to the tetrahedral structure of the phosphonic acid moiety since they act as 'transition-state analogues' in enzymatic hydrolysis.² Conformationally constrained amino acids have been the focus of both synthetic and medicinal chemistry; in particular the cyclopropane ring has served as a useful segment in peptidomimetic design.³ This system affects the chemical and biological properties in peptides through significant conformational restrictions in the amino acid residues.⁴ It has also been found that constrained amino acids can be highly potent and specific agonists since they closely mimic the bioactive conformation of natural neurotransmitters.⁵ Aminocyclopropanephosphonic acids combining both unique properties (conformational restriction and isosterism) have thus motivated several research groups to study cyclopropanephosphonates as active analogues, affording improved pharmaceutical properties in certain cases.⁶ Since they have not received the same attention^{7,8} compared to acyclic aminophosphonic acids **1** and aminocyclopropanecarboxylic acids **2** (Fig. 1), a new approach to this type of compounds requires further investigation.

We have already reported on the synthesis of conformationally constrained analogues of bioactive amino acids based on asymmetric cyclopropanation utilizing optically active sulfinyl compounds.⁹ Herein we turned our attention to 1-aminocyclopropanephosphonic acids, applying (*S*)-dimethylsulfonium-(*p*-tolylsulfinyl)methylide **6**, designed and described by us earlier,¹⁰ as a chiral sulfur reagent in the cyclopropanation step. In order to introduce chirality to the structure of 1-aminocyclopropanephosphonic

acids, differentiation of the enantiotopic methylene groups was attained by the presence of two deuterium atoms on one of them (dideuterated ACPP). Although different syntheses of deuterium labeled 1-aminocyclopropane-1-carboxylic acid have been reported,¹¹ the phosphonic analogue in the deuterated version has not been described.

2. Results and discussion

Cyclopropanation of phosphoryl acrylates **7-d₂** and **8-d₂** using (*S*)-dimethylsulfonium-(*p*-tolylsulfinyl)methylide **6** afforded a separable mixture of three diastereomers **9-d₂** (**A-C**) and **10-d₂** (**A-C**) in a ratio dependent on the conditions used for ylide generation (Scheme 1). Comparison of the spectroscopic data of the resulting diastereomers with those of the non-deuterated analogues described earlier¹² allowed us to determine their configuration.

In order to remove the chiral auxiliary, cyclopropane **10A-d₂** was subjected to sulfoxide/metal exchange, a reaction that has been widely applied for the synthesis of enantiomerically pure sulfoxides, and also as a method to generate the corresponding carbanions. Due to the presence of other reactive centers in cyclopropyl sulfoxide **10**, isopropylmagnesium chloride was used as the reagent of choice. When the reaction was performed at –10 °C in diethyl ether for 20 min, it gave confusing results: the formation of two major products with the same molecular weight. Since the desired product contains only one stereogenic center, the second product must be its regioisomer. Initially, we assumed that after the attack of the Grignard reagent on the sulfinyl group, the carbanionic species formation involved a shift of one of the deuterium atoms to the neighboring carbon atom, resulting in the formation of structure **11**.¹² This hypothesis was later discarded and the correct explanation of this phenomenon was established on the basis of our previous investigations concerning sulfinyl group removal from mono-methylated sulfinylcyclopropanes.¹³ In that

* Corresponding author. Tel./fax: +48 42680 3216.

E-mail address: whmidura@cbmm.lodz.pl (W.H. Midura).





Figure 1.



entry	Reaction conditions	Product	Ratio of diast.				Facial selectivity
			A	B	C	D	
1.	NaH/MeCN 0–20 °C	9-d₂	64	23	13	-	87 : 13
2.	NaH / MeCN 0 °C	9d₂	68	27	5	-	95 : 5
3.	K ₂ CO ₃ / CH ₂ Cl ₂ rt.	9-d₂	62	26	12	-	88 : 12
4.	NaH / MeCN 0 °C	10-d₂	62	28	10	-	90 : 10
5.	K ₂ CO ₃ / CH ₂ Cl ₂ rt.	10-d₂	65	21	14	-	86 : 14

Scheme 1. Cyclopropanation of vinylphosphonates with (S)-dimethylsulfonium-(p-tolylsulfinyl)methylide.


case, the formation of regioisomers of the desired products was explained in terms of an unprecedented 1,2-migration of a phosphoryl group on the cyclopropane ring. We found that the same rearrangement took place for cyclopropane **10**, but that the reaction course was temperature dependent. At a low temperature (–50 °C), the desulfinylated cyclopropane **12** was observed as the only product, whereas increasing the temperature and extending the reaction time led to the formation of regioisomer **13** (Scheme 2).

Taking advantage of this observation, our further investigations were performed at a lower temperature (–50 °C); due to slightly better induction during cyclopropanation, (Scheme 1 entry 2) ethyl ester **9A-d₂** was used for the next set of conversions. The desired desulfinylated product **14-d₂** was obtained exclusively in high yield.


The most typical synthetic approach to aminophosphonic acids utilizes the Curtius rearrangement,¹⁴ where the carboxyl group can be converted into the corresponding acid chlorides and then, with

sodium azide, converted into an acyl azide, which is subjected to Curtius rearrangement. Thus, the hydrolysis of the ester **14-d₂** with lithium hydroxide at room temperature gave acid **15-d₂**, which was used for the next step without purification. Since our preliminary experiment on undeuterated product **15** led to the formation of some by-products, we used the alternative procedure of the Curtius rearrangement using diphenylphosphoryl azide.¹⁵ The reaction was carried out by boiling equimolar amounts of cyclopropanecarboxylic acid **9A-d₂**, diphenylphosphoryl azide, and triethylamine in *t*-BuOH and afforded the *N*-Boc-protected amino ester **16-d₂**. The latter, upon treating with 6 N hydrochloric acid and subsequent addition of propylene oxide and ethanol, afforded the desired aminocyclopropane-1-phosphonic acid **17-d₂** (Scheme 3).


Examination of the ¹H NMR spectra of the deuterated compounds obtained for each step of the synthesis, confirmed the substitution of the methylenic protons by deuterium, since the resonances corresponding to these protons were absent. Even



Scheme 2. Sulfenyl exchange.



Scheme 3.

Figure 2. ^{13}C NMR of $(-)-(1R)$ -ethyl-1-diethylphosphono-2,2,2 H_2 -cyclopropanecarboxylate **14-d₂**.

more diagnostic was ^{13}C NMR, where both methylene carbons were different (CH_2 vs CD_2). However, to make it more visible in some cases, deuterium decoupling was required (Fig. 2).

3. Conclusion

In conclusion, we have reported on the asymmetric synthesis of cyclopropyl phosphonates using the (S) -dimethylsulfonium- $(p$ -tolylsulfinyl)methylide **6** and reaction sequences that demonstrate that these products are well-suited to the synthesis of the cyclopropyl analogues of aminophosphonic acids. An elaborated procedure of desulfinylation allowed us to avoid 1,2-migration of a phosphoryl group on a cyclopropane ring and obtain the cyclopropyl phosphonate with the retained structure and configuration.

Employment of a Curtius procedure resulted in the formation of enantiopure $(+)-(1R)$ -1-amino-2,2-dideuteriocyclopropanephosphonic acid **(+)-17-d₂**, which is the first approach to this deuterium labeled analogue.

4. Experimental

4.1. General

^1H , ^{13}C , and ^{31}P NMR spectra were recorded on a Bruker Avance III 600, Bruker Avance III 500, and Bruker AC 200 Spectrometer, using deuteriochloroform as solvent. Mass spectra were recorded on Finnigan MAT95. IR spectra were recorded on Ati Mattson FTIR Spectrometer. The optical rotations were measured on a Perkin-El-

mer 241 MC photopolarimeter in acetone solution. The microanalyses were performed on Elemental Analyzer EA 1108. TLC was carried out on silica gel plates (Merck F254) and silica gel 60 (70–230 ASTM) was used for chromatography. THF was freshly distilled over potassium/benzophenone.

4.2. Cyclopropanation

To a round-bottomed flask equipped with a magnetic stirrer bar were added 2 mmol (0.48 g) of ethyl-1-diethylphosphono-2,2-dideuteroacrylate and 2 mmol (0.6 g) of (*S*)-dimethyl sulfonium-(*p*-tolylsulfinyl)methyl tetrafluoroborate placed in 10 mL of CH₂Cl₂. To this suspension was added 0.3 g of K₂CO₃ and the mixture was stirred vigorously overnight. Filtration and evaporation of the solvent afforded a crude residue in 95% yield. Separation of the diastereomers was achieved by chromatography on silica (hexane/acetone 2:1).

4.2.1. (+)-(1*R*,2*S*,*Ss*)-Ethyl-1-diethylphosphono-2-*p*-tolylsulfinyl-3,3-²H₂-cyclopropanecarboxylate 9A-d₂

Yield 53%; yellowish oil; $[\alpha]_D^{20} = +79$ (c 13.6, acetone); ³¹P NMR (81 MHz, CDCl₃) δ : 18.8; ¹H NMR (500 MHz, CDCl₃) δ : 1.23 (t, 3H, POCH₂CH₃, *J*_{HH} = 7.0 Hz), 1.28 (t, 3H, POCH₂CH₃, *J*_{HH} = 7.0 Hz), 1.32 (t, 3H, COCH₂CH₃, *J*_{HH} = 7.1 Hz), 2.42 (s, 3H, C₆H₄CH₃), 2.90 (d, 1H, *J*_{PH} = 15.2 Hz, CHS(O)), 3.89–3.94 (m, 1H, POCHHCH₃), 4.0–4.03 (m, 1H, POCHHCH₃), 4.07–4.14 (m, 2H, POCH₂CH₃), 4.26 (q, 2H, COCH₂CH₃, *J*_{HH} = 7.1 Hz), 7.32 and 7.58 (A₂B₂, 4H, C₆H₄CH₃); ¹³C NMR (125 MHz, CDCl₃): 12.7 (m, CD₂), 14.1 (CH₃CH₂OC), 16.3 (m, CH₃CH₂OP), 21.5 (C₆H₄CH₃), 27.5 (CP, d, *J*_{CP} = 181.0 Hz), 44.6 (CHSO), 62.5 (CH₃CH₂OC), 63.1 (d, *J*_{CP} = 6.0 Hz, CH₃CH₂OP), 63.4 (d, *J*_{CP} = 6.7 Hz, CH₃CH₂OP), 124.3, 130.0, 140.8, 142.1, 165.7 (d, *J*_{CP} = 7.7 Hz); MS(Cl) *m/z* 391 (M+H)⁺; HR MS(ES) 413.1133 calcd for C₁₇H₂₃²H₂O₆NaPS [M+Na]⁺ found: 413.1128.

4.2.2. (+)-(1*S*,2*R*,*Ss*)-Ethyl-1-diethylphosphono-2-*p*-tolylsulfinyl-3,3-²H₂-cyclopropanecarboxylate 9C-d₂

Yield 8%; yellowish oil; $[\alpha]_D^{20} = +120$ (c 10.1, acetone); ³¹P NMR (81 MHz, CDCl₃) δ : 18.7; ¹H NMR (500 MHz, CDCl₃) δ : 1.33 (t, 3H, POCH₂CH₃, *J*_{HH} = 7.0 Hz), 1.34 (t, 3H, POCH₂CH₃, *J*_{HH} = 7.0 Hz), 1.37 (t, 3H, COCH₂CH₃, *J*_{HH} = 7.1 Hz), 2.43 (s, 3H, C₆H₄CH₃), 3.08 (d, 1H, *J*_{PH} = 13.9 Hz, CHS(O)), 4.07–4.14 (m, 4H, POCH₂CH₃), 4.4 (m, 2H, COCH₂CH₃), 7.33 and 7.58 (A₂B₂, 4H, C₆H₄CH₃); ¹³C NMR (125 MHz, CDCl₃): 14.0 (CH₃CH₂OC), 14.9 (m, CD₂), 16.3 (d, *J*_{CP} = 5.8 Hz, CH₃CH₂OP), 16.4 (d, *J*_{CP} = 6.7 Hz, CH₃CH₂OP), 21.4 (C₆H₄CH₃), 27.0 (d, *J*_{CP} = 181.9 Hz), 48.0 (CHSO), 62.7 (CH₃CH₂OC), 63.4 (m, CH₃CH₂OP), 124.2, 130.1, 140.8, 142.0, 166.2 (d, *J*_{CP} = 5.2 Hz); MS(Cl) *m/z* 391 (M+H)⁺; HR MS(ES) 413.1133 calcd for C₁₇H₂₃²H₂O₆NaPS [M+Na]⁺ found: 413.1135.

4.2.3. (–)-(1*S*,2*S*,*Ss*)-Ethyl-1-diethylphosphono-2-*p*-tolylsulfinyl-3,3-²H₂-cyclopropanecarboxylate 9B-d₂

Yield: 20%; yellowish oil; $[\alpha]_D^{20} = -32$ (c 7.4, acetone); ³¹P NMR (81 MHz, CDCl₃) δ : 17.3 ppm; ¹H NMR (500 MHz, CDCl₃) δ : 1.20 (t, 3H, POCH₂CH₃, *J*_{HH} = 7.2 Hz), 1.31 (t, 3H, POCH₂CH₃, *J*_{HH} = 7.0 Hz), 1.34 (t, 3H, COCH₂CH₃, *J*_{HH} = 7.0 Hz), 2.38 (s, 3H, C₆H₄CH₃), 3.00 (d, 1H, *SCH*, *J*_{PH} = 9.0 Hz), 4.09–4.26 (m, 6H, OCH₂CH₃), 7.29 and 7.74 (A₂B₂ aromatic); ¹³C NMR (125 MHz, CDCl₃): 13.8 (CH₃CH₂OC), 16.3 (m, CH₃CH₂OP), 18.1 (m, CD₂), 21.3 (C₆H₄CH₃), 27.6 (d, *J*_{CP} = 195.7 Hz), 49.7 (CHSO), 62.4 (CH₃CH₂OC), 62.9 (d, *J*_{CP} = 6.2 Hz, CH₃CH₂OP), 63.4 (d, *J*_{CP} = 6.5 Hz, CH₃CH₂OP), 124.5, 129.9, 141.6, 142.1, 167.5 (d, *J*_{CP} = 7.7 Hz); MS(Cl) *m/z* 391 (M+H)⁺.

4.2.4. (+)-(1*R*,2*S*,*Ss*)-*t*-Butyl-1-dimethylphosphono-2-*p*-tolylsulfinyl-3,3-²H₂-cyclopropanecarboxylate 10A-d₂

Yield: 50%; white solid; mp 92–94 °C; $[\alpha]_D^{20} = +86.8$ (c 1.0, acetone); ³¹P NMR (81 MHz, CDCl₃) δ 22.5; ¹H NMR (200 MHz, CDCl₃)

δ : 1.52 (s, 9H, COC(CH₃)₃), 2.41 (s, 3H, C₆H₄CH₃), 2.87 (d, 1H, *J*_{PH} = 15.4 Hz, CHS(O)), 3.64 and 3.77 (2 × d, 6H, POCH₃, *J*_{PH} = 11.1 Hz), 7.32 and 7.75 (AB, 4H, C₆H₄CH₃, *J*_{HH} = 8.1 Hz); ¹³C NMR (125 MHz, CDCl₃): 12.1 (CD₂, quint, *J*_{CD} = 25.5 Hz), 21.2 (C₆H₄CH₃), 27.6 ((CH₃)₃C), 27.7 (d, *J*_{CP} = 180.4 Hz), 44.0 (CHS, d, *J*_{CP} = 3.2 Hz), 53.3 (d, *J*_{CP} = 6.0 Hz), 53.5 (d, *J*_{CP} = 6.0 Hz), 83.6 ((CH₃)₃C), 124.1, 129.9, 140.6, 141.8, 164.0 (C=O, d, *J*_{CP} = 4.8 Hz); MS(Cl) *m/z* 391 (M+H)⁺. HR MS(FAB) 390.1235 calcd for C₁₇-¹H₂₃²H₂O₆PS [M]⁺ Found 390.1239.

4.2.5. (–)-(1*S*,2*S*,*Ss*)-*t*-Butyl-1-dimethylphosphono-2-*p*-tolylsulfinyl-3,3-²H₂-cyclopropanecarboxylate 10C-d₂

Yield: 21%; yellowish oil; $[\alpha]_D^{20} = -38.7$ (c 3.1 acetone); ³¹P NMR (81 MHz, CDCl₃) δ 20.6; ¹H NMR (500 MHz, CDCl₃) δ : 1.39 (s, 9H, COC(CH₃)₃), 2.40 (s, 3H, C₆H₄CH₃), 2.91 (d, 1H, *J*_{HH} = 9.4 Hz, CHS(O)), 3.79 and 3.82 (2 × d, 6H, POCH₃, *J*_{HH} = 11.1 Hz), 7.32 and 7.75 (A₂B₂, 4H, C₆H₄CH₃, *J*_{HH} = 8.1 Hz); ¹³C NMR (125 MHz, CDCl₃): 17.1 (quint, *J*_{CD} = 25.5 Hz), 21.2, 27.6, 28.9 (d, *J*_{CP} = 196.0 Hz), 48.8 (d, *J*_{CP} = 3.2 Hz), 53.0 (d, *J*_{CP} = 6.1 Hz), 53.5 (d, *J*_{CP} = 6.9 Hz), 83.45, 124.2, 129.8, 141.3, 141.4, 165.8 (d, *J*_{CP} = 6.8 Hz); MS(Cl) *m/z* 391 (M+H)⁺; HR MS(FAB) 390.1235 calcd for C₁₇¹H₂₃²H₂O₆PS [M]⁺ found: 390.1230.

4.3. Sulfinyl exchange

At the indicated temperature under nitrogen, to a stirred solution of (+)-9A-d₂ or (+)-10A-d₂ (0.2 mmol) in anhydrous Et₂O (3.0 mL), *i*-PrMgCl (2.0 M in Et₂O, 1 mmol, 0.11 mL), was added and the mixture was stirred at –50 °C for 1 h. The reaction was quenched by NH₄Cl, and extracted with Et₂O (3 × 5 mL). The combined extracts were dried over anhydrous MgSO₄, filtered, and concentrated. Purification was performed by plate chromatography (hexane/acetone 3:1)

4.3.1. (–)-(1*R*)-Ethyl-1-diethylphosphono-2,2-²²H₂-cyclopropanecarboxylate 14-d₂

Yield: 83%; yellowish oil; $[\alpha]_D^{20} = -4.5$ (c 6.7, acetone); ³¹P NMR (81 MHz, CDCl₃) δ 23.5; ¹H NMR (500 MHz, CDCl₃) δ : 1.25 (t, 3H, POCH₂CH₃, *J*_{HH} = 7.1 Hz), 1.29 (t, 6H, COCH₂CH₃, *J*_{HH} = 7.0 Hz), 1.39–1.43 (m, 2H, CH₂), 4.12–4.18 (m, 6H, OCH₂CH₃); ¹³C NMR (125 MHz, CDCl₃): 14.0 (CH₃CH₂OC), 14.6 (CD₂), 14.9 (CH₂), 16.2 (CH₃CH₂OP), 16.3 (d, *J*_{CP} = 6.0 Hz, CH₃CH₂OP), 19.1 (d, *J*_{CP} = 199.4 Hz), 61.4 (CH₃CH₂OC), 62.5 (d, *J*_{CP} = 6.0 Hz, CH₃CH₂OP), 62.6 (CH₃CH₂OP), 170.1 (C=O); MS(Cl) *m/z* 253 (M+H)⁺; MS(ES) 275.0993 calcd for C₁₀¹H₁₇²²H₂O₅PNa [M+Na]⁺ found: 275.0992

4.3.2. (+)-(1*R*)-*t*-Butyl-1-dimethylphosphono-2,2-²H₂-cyclopropanecarboxylate 12-d₂

Yield: 82%; yellowish oil; $[\alpha]_D^{20} = +1.7$ (c 1.0, acetone); ³¹P NMR (81 MHz, CDCl₃) δ 28.3; ¹H NMR (500 MHz, CDCl₃) δ : 1.31–1.40 (m, 2H, CH₂), 1.45 (s, 9H, (CH₃)₃CO), 3.78 (d, 6H, POCH₃, *J*_{PH} = 11.1 Hz); ¹³C NMR (125 MHz, CDCl₃): 13.9 (quint, *J*_{CD} = 25.4 Hz), 14.4, 19.2 (d, *J*_{CP} = 198.8 Hz), 27.9, 53.3 (d, *J*_{CP} = 6.2 Hz), 82.0, 168.8 (d, *J*_{CP} = 8.3 Hz); MS(Cl) *m/z* 253 (M+H)⁺; MS(FAB) 252.1096 calcd for C₁₀¹H₁₇²H₂O₅P [M]⁺ found: 252.1105

4.3.3. (+)-(1*S*,2*R*)-*t*-Butyl-3,3-²H₂-2-dimethylphosphonocyclopropanecarboxylate 13-d₂

Yield: 48%; yellowish oil; $[\alpha]_D^{20} = -124.2$ (c 1.7, acetone); ³¹P NMR (202 MHz, CDCl₃) δ : 30.6; ¹H NMR (500 MHz, CDCl₃) δ : (dd, 1H, CHtrans, *J*_{HH} = 4.8, 5.0 Hz), 1.43 (s, 9H, (CH₃)₃CO), 2.05 (dd, 1H, CHcis, *J*_{HH} = 4.8, *J*_{PH} = 14.8 Hz), 3.74 and 3.75 (2 × d, 6H, POCH₃, *J* = 10.8 Hz) ¹³C NMR (125 MHz, CDCl₃): 10.7 (CD₂, quint, *J*_{CD} = 25.5 Hz), 12.0 (CP=O, d, *J*_{CP} = 195.5 Hz), 18.6, 28.0 ((CH₃)₃CO), 52.7 (t, *J*_{CP} = 5.7 Hz), 81.4, 171.0 (d, *J*_{CP} = 10.8 Hz); MS(Cl) *m/z* 253

(M+H)⁺; MS(FAB) 252.1096 calcd for C₁₀H₁₇O₅P [M]⁺ found: 252.1098.

4.4. (–)-(1R)-1-Diethylphosphono-2,2-²H₂-cyclopropane-*tert*-butoxycarbonylamine

At first, 76 mg of ethyl ester **14-d₂** (0.3 mmol) was dissolved in 5 mL of aqueous solution of LiOH. The mixture was then stirred for 1 h at room temperature. Next to the solution was added 5% HCl. The water phase was extracted with CHCl₃ (5 × 5 mL). The combined organic phases were dried over MgSO₄ and the solvent was evaporated. The crude carboxylic acid derivative (62 mg, 0.28 mmol) and NEt₃ (40 μL, 0.28 mmol) were mixed with dry *t*-BuOH (5 mL) at 25 °C under N₂. Diphenylphosphoryl azide (76 mg, 0.28 mmol) was then added, and the reaction mixture was refluxed with stirring for 12 h. The reaction solution was concentrated, and the crude product extracted with ether. After being washed with 1 M HCl and saturated NaHCO₃(aq) and dried, the product was purified by chromatography on silica (hexane/acetone 4:1). Yield: 88%; colorless oil; [α]_D²⁰ = –0.3 (c 2.6, acetone); ³¹P NMR (81 MHz, CDCl₃) δ 25.5; ¹H NMR (500 MHz, CDCl₃) δ: 1.32 (2 × t, 6H, POCH₂CH₃, J_{HH} = 7.0 Hz), 1.35–1.50 (m, 2H, CH₂), 1.42 (s, 9H, COC(CH₃)₃), 4.12–4.19 (m, 4H, POCH₂CH₃), 4.95 (s, 1H, NH); ¹³C NMR (125 MHz, CDCl₃): 12.9 (CH₂), 14.1 (CD₂), 16.3 (CH₃CH₂OP), 16.4 (d, J_{CP} = 6.2 Hz, CH₃CH₂OP), 25.2, 27.0 (d, J_{CP} = 221.1 Hz), 28.2 (COC(CH₃)₃), 61.6 (CH₃CH₂OC), 62.5 (CH₃CH₂OP), 62.6 (d, J_{CP} = 5.5 Hz, CH₃CH₂OP), 79.8 (COC(CH₃)₃), 155.0 (C=O) MS(Cl) *m/z* 297 (M+H)⁺; HR MS(FAB) 296.1596 calcd for C₁₂H₂₃O₅NP [M]⁺ found: 296.1586.

4.5. (–)-(1R)-1-Amino-[2,2-²H₂]-cyclopropane-1-phosphonic acid **17-d₂**

A solution of *N*-Boc-protected cyclopropylamine **16-d₂** (27 mg) in 2 mL of 6 N HCl was heated at 100 °C for 24 h and then concentrated under vacuum. The residue was dissolved in absolute ethanol (0.5 mL) and then treated with propylene oxide (0.04 mL). After standing overnight at room temperature, the mixture was filtered to afford a white solid. [α]_D²⁰ = –1.3 (c 1.2, H₂O); ³¹P NMR (81 MHz, D₂O) δ 12.4 ¹H NMR (500 MHz, CDCl₃) δ: 1.02–1.11 (m, 2H, CH₂), ¹³C NMR (125 MHz, D₂O): 8.8 (CD₂), 8.9 (CH₂), 30.4 (d, J_{CP} = 191.3 – Hz) (lit.¹⁶ for undeuterated acid δ 30.9, d, J_{CP} = 193.5 Hz); MS(FAB) *m/z* 139 M⁺.

Acknowledgements

We gratefully acknowledge financial support from the Ministry of Science and Higher Education No N N204 257938. The authors are indebted to Dr Sławomir Kaźmierski for technical support.

References

- For a recent review see (a) Mucha, A.; Kafarski, P.; Berlicki, Ł. *J. Med. Chem.* **2011**, *54*, 5955–5980; (b) Orsini, F.; Sello, G.; Sisti, M. *Curr. Med. Chem.* **2010**, *17*, 264–289; (c) Ordonez, M.; Rojas-Cabrera, H.; Cativiela, C. *Tetrahedron* **2009**, *65*, 17–49; (d) Berlicki, Ł.; Kafarski, P. *Curr. Org. Chem.* **2005**, *9*, 1829–1850.
- Jacobsen, N. E.; Bartlett, P. A. *J. Am. Chem. Soc.* **1981**, *103*, 654–657.
- (a) Brackmann, F.; de Mejere, A. *Chem. Rev.* **2007**, *107*, 4493–4537; (b) Cativiela, C.; Diaz-de-Villegas, M. D. *Tetrahedron: Asymmetry* **2000**, *11*, 645–732.
- For example employing cyclopropane ring constraint in a peptides, see (a) Burgess, K.; Ho, K.-K.; Pettitt, B. M. *J. Am. Chem. Soc.* **1995**, *117*, 54–65; (b) Burgess, K.; Ke, C.-Y. *J. Org. Chem.* **1996**, *61*, 8627–8631.
- (a) Pellicciari, R.; Marinuzzi, M.; Natalini, B.; Costantino, G.; Luneia, R.; Giorgi, G.; Moroni, F.; Thomsen, C. *J. Med. Chem.* **1996**, *39*, 2259–2269; (b) Pellicciari, R.; Marinuzzi, M.; Camaioni, E.; Nunez, M.; Costantino, G.; Gasparini, F.; Giorgi, G.; Macchiarulo, A.; Subramanian, N. *J. Org. Chem.* **2002**, *67*, 5497–5507.
- (a) Pompei, M.; Di Francesco, M. E.; Koch, U.; Liverton, N. J.; Summa, V. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 2574–2578; (b) Sheng, X. C.; Pyun, H.; Chaudhary, K.; Wang, J.; Doerffler, E.; Fleury, M.; McMurtrie, D.; Chen, X.; Delaney, I. W. E.; Kim, C. U. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 3453–3457; (c) Pyun, H.-J.; Clarke, M. O.; Cho, A.; Casarez, A.; Ji, M.; Fardis, M.; Pastor, R.; Sheng, X. C.; Kim, C. U. *Tetrahedron Lett.* **2012**, *53*, 2360–2363.
- Gulyukina, N. S.; Makukhin, N. N.; Beletskaya, I. P. *Zh. Org. Khim.* **2011**, *47*, 633–648, and references cited therein.
- (a) Wasek, K.; Kędzia, J.; Krawczyk, H. *Tetrahedron: Asymmetry* **2010**, *21*, 2081–2086; (b) Hercouet, A.; Le Corre, M.; Carboni, B. *Tetrahedron Lett.* **2000**, *41*, 197–199; (c) Tesson, N.; Dorigneux, B.; Fadel, A. *Tetrahedron: Asymmetry* **2002**, *13*, 2267–2276.
- (a) Midura, W. H.; Mikołajczyk, M. *Tetrahedron Lett.* **2002**, *43*, 3061–3065; (b) Krysiak, J.; Midura, W. H.; Wiecek, W.; Sieroń, L.; Mikołajczyk, M. *Tetrahedron: Asymmetry* **2010**, *21*, 1486–1493; (c) Midura, W. H.; Krysiak, J. A.; Rzewnicka, A.; Supel, A.; Łyżwa, P. *Tetrahedron* **2013**, *69*, 730–737.
- (a) Midura, W. H. *Synlett* **2006**, 733–736; (b) Midura, W. H. *Tetrahedron Lett.* **2007**, *48*, 3907–3910; (c) Midura, W. H.; Cypryk, M. *Tetrahedron: Asymmetry* **2010**, *21*, 177–186.
- (a) Hill, R. H.; Prakash, S. R.; Wiesendanger, R.; Angst, W.; Martinoni, B.; Arigoni, D.; Liu, H. W.; Walsh, C. T. *J. Am. Chem. Soc.* **1984**, *106*, 795–796; (b) Williams, R. M.; Fegley, G. J. *J. Am. Chem. Soc.* **1991**, *113*, 87; (c) Buñuel, E.; Bull, S. D.; Davies, S. G.; Christopher Garner, A. C.; Savory, E. D.; Smith, A. D.; Richard, J.; Vickers, R. J.; Watkin, D. *J. Org. Biomol. Chem.* **2003**, *1*, 2531–2542.
- Midura, W. H. *Phosphorus, Sulfur and Silicon* **2011**, *186*, 1189–1192.
- Midura, W. H.; Sobczak, A.; Paluch, P. *Tetrahedron Lett.* **2013**, *54*, 223–226.
- Moore, J. D.; Sprott, K. T.; Hanson, P. R. *J. Org. Chem.* **2002**, *67*, 8123–8129.
- Shioiri, T.; Ninomiya, K.; Yamada, S. *J. Am. Chem. Soc.* **1972**, *94*, 6203–6205.
- Fadel, A. *J. Org. Chem.* **1999**, *64*, 4953–4955.